Biogen Inc.
Biogen Announces Agreement to Merge with Apellis Pharmaceuticals
Summary
On March 31, 2026, Biogen Inc. announced an agreement to merge with Apellis Pharmaceuticals, Inc. The merger involves a tender offer for Apellis's common stock at $41.00 per share in cash, plus one contingent value right per share, which entitles the holder to potential payments of up to an aggregate of $4.00 upon the achievement of certain sales milestones. The merger is supported by certain stockholders, including Morningside Venture Investments, Ltd., who hold approximately 14% of Apellis's outstanding shares. The merger is expected to be completed through a short-form merger under Delaware law, with no stockholder vote required.
Profitelligence Alerts
Get alerts for BIIB
Be first to know when Biogen Inc. files with the SEC.
Filing Categories
Advertisement
About Biogen Inc.
Biogen Inc. is a globally recognized biotechnology company committed to discovering, developing, and delivering innovative therapies for neurological diseases. With a focus on serious medical conditions, Biogen creates therapies aimed at treating conditions like multiple sclerosis, Alzheimer's disease, and spinal muscular atrophy. The company invests heavily in research and development to pioneer treatments that improve patients' quality of life and addresses critical unmet medical needs. Biogen's influence spans various therapeutic areas in the healthcare sector, making notable strides in both neurodegenerative and rare diseases. The company's portfolio includes a range of biologics, gene therapy, and small molecule drugs, highlighting its strategic diversity. As a prominent player within the biopharmaceutical industry, Biogen collaborates with academic institutions, research organizations, and other biotech firms to enhance its research pipeline and bring new solutions to market. Biogen's role in the financial markets is underscored by its contributions to healthcare innovation and its impact on global health outcomes. Headquartered in Cambridge, Massachusetts, Biogen continues to leverage its scientific expertise and industry alliances to remain at the forefront of biotechnology, influencing both investors and the broader medical community.
Official SEC Documents
Advertisement